Scholarlink

Background <p>Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality. Intravenous doxorubicin (DOX) is effective but limited by severe cardiotoxicity and poor lung tumor selectivity.</p> Objective <p>To develop an inhalable dry powder inhaler (DPI) of DOX-loaded PLGA-PEG dual-coated micelles embedded in a lactose/trehalose matrix for targeted pulmonary delivery and reduced systemic toxicity.</p> Methods <p>Micelles were prepared via nanoprecipitation and engineered into respirable powders via spray-drying. Formulations were characterized for size, stability, aerosol performance, drug release, and cytotoxicity (SLC cells). <i>In vivo</i> pharmacokinetics, lung deposition, antitumor efficacy, and systemic safety were assessed in rat models.</p> Results <p>Optimized micelles showed high encapsulation efficiency (91.3%), desirable aerodynamic properties (MMAD 2.9&#xa0;μm, FPF 62.4%), and sustained biphasic release. They significantly enhanced cytotoxicity (IC₅₀ 1.82 vs. 3.96&#xa0;µg/mL) and apoptosis (48.6% vs. 29.7%) compared to free DOX. <i>In vivo</i>, pulmonary delivery achieved 46.8% lung retention at 24&#xa0;h (vs. 12.4%), prolonged systemic residence time (MRT 14.7&#xa0;h vs. 6.1&#xa0;h), and superior tumor growth inhibition (68.5% vs. 25.3%). Critically, micellar DOX markedly reduced cardiotoxicity (CK-MB ↓55%, LDH ↓48%) with minimal histopathological cardiac damage.</p> Conclusion <p>The spray-dried micellar DPI platform enables efficient lung-targeted delivery of DOX, enhancing antitumor efficacy while mitigating systemic cardiotoxicity, presenting a promising therapeutic strategy for NSCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineered Spray-Dried PLGA-PEG Dual-Coated Micelles with Lactose/Trehalose Matrices for Pulmonary Doxorubicin Delivery: Achieving Sustained Release and Improved Aerosol Performance in NSCLC Therapy

  • 期刊论文

  • 发表日期：

    2026年2月27日

查看全文
  • Randa Mohammed Zaki,
  • Alaa Ayman,
  • Eman Mostafa Samy,
  • Mahmoud Mohamed Omar,
  • Obaid Afzal,
  • Rawan Bafail,
  • Waad A. Samman,
  • Omiya A. Hasan

摘要

Background

Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality. Intravenous doxorubicin (DOX) is effective but limited by severe cardiotoxicity and poor lung tumor selectivity.

Objective

To develop an inhalable dry powder inhaler (DPI) of DOX-loaded PLGA-PEG dual-coated micelles embedded in a lactose/trehalose matrix for targeted pulmonary delivery and reduced systemic toxicity.

Methods

Micelles were prepared via nanoprecipitation and engineered into respirable powders via spray-drying. Formulations were characterized for size, stability, aerosol performance, drug release, and cytotoxicity (SLC cells). In vivo pharmacokinetics, lung deposition, antitumor efficacy, and systemic safety were assessed in rat models.

Results

Optimized micelles showed high encapsulation efficiency (91.3%), desirable aerodynamic properties (MMAD 2.9 μm, FPF 62.4%), and sustained biphasic release. They significantly enhanced cytotoxicity (IC₅₀ 1.82 vs. 3.96 µg/mL) and apoptosis (48.6% vs. 29.7%) compared to free DOX. In vivo, pulmonary delivery achieved 46.8% lung retention at 24 h (vs. 12.4%), prolonged systemic residence time (MRT 14.7 h vs. 6.1 h), and superior tumor growth inhibition (68.5% vs. 25.3%). Critically, micellar DOX markedly reduced cardiotoxicity (CK-MB ↓55%, LDH ↓48%) with minimal histopathological cardiac damage.

Conclusion

The spray-dried micellar DPI platform enables efficient lung-targeted delivery of DOX, enhancing antitumor efficacy while mitigating systemic cardiotoxicity, presenting a promising therapeutic strategy for NSCLC.